(MENAFN- Investor Brand Network)
- Avricore Health is developing a variety of pharmacy services that provide lab-quality testing for pre-diabetes and cardiovascular concerns
- The company's trademarked HealthTab platform makes advanced testing technologies available to partner pharmacies and, through them, to patients at accessible point-of-care (“POC”) locations
- HealthTab's partnership with Abbott Diagnostics in Canada also has the potential to expand to virus testing for COVID, RSV, influenza A and B, and strep
- The company has located the systems in Ontario and British Columbia through an agreement with large national pharmaceutical chain Shoppers Drug Mart, and anticipates expansion to other Shoppers Drug sites with 600 locations established by the end of 2023
- Avricore also expects to forge agreements that will take HealthTab's POC testing to pharmacies in the United States, United Kingdom and European Union
Health diagnostics solutions innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is celebrating its achievement of key milestones this year, building on its initial agreement with Canada's Shoppers Drug Mart pharmaceutical chain to make its platform technology accessible to patients across the country.
Avricore's milestones include building an agreement with Abbott Diagnostics to establish in-store kiosks that utilize Avricore's platform, allowing Avricore to test its platform in pilot stage and roll it out to the…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company's newsroom at
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you'll need to ensure that your next press release grabs the attention of your target audience and doesn't let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement .
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork .
Get more out of your next press release with InvestorWire. It's unlike anything you've seen before.
For more information, please visit
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
InvestorWire is part of the InvestorBrandNetwork .
MENAFN24112021000224011066ID1103246942
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.